Windward Bio shares close 68% above $17 IPO price on Nasdaq debut
SHANGHAI -- November 16, 2026 -- Windward Bio, a clinical-stage biotechnology company founded in 2024, closed its first Nasdaq trading day on November 13, 2026 at $28.50 per share, 68% above its $17.00 IPO price. The $11.50 gain per share lifted the company's market capitalization to about $1.69 billion, against roughly $1.01 billion at the offer price by our calculation.
The $1.69 billion figure works out to about 59 million shares ($1.69 billion divided by $28.50), assuming the release values the company at the closing price. The company trades as WWB. It did not disclose the gross proceeds of the offering.
Qiming Venture Partners backed Windward Bio from Series A through the IPO
Qiming Venture Partners invested in Windward Bio's Series A in 2025 and its Series B in 2026, and it took part in the IPO round. The listing is Qiming's 11th IPO in 2026. Windward Bio reached the public market about two years after its 2024 founding.